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FBG          fasting blood glucose 
2HPBG       2hour post breakfast blood glucose  
3HPBG       3hour post breakfast blood glucose  
HbA1c        glycated haemoglobin A1c 
NEFA                 Non esterified fatty acid 
MODY               Maturity onset diabetes of the young 
GLUT                 Glucose uptake transporter  
SGLT                 Sodium sensitive Glucose transporter 
CVD                    Cardiovascular disease 
CHD                   Coronary heart disease  
UAER                 Urinary albumin excretion rate  
GAD                    Glutamic acid decarboxylase  
ICA                     Islet cell antibodies 
IFG                      Impaired fasting glucose 
IGT                     Impaired glucose tolerance 
IAPP                   islet amyloid polypeptide 
WHR                   Waist hip ratio 
FFA                     Free fatty acid 
AACE                 American association of clinical endocrinologist  
SU                      Sulfonylurea 
SUR                   Sulfonylurea receptor 
TZDS                  Thiazolidinediones 
PPAR                   Perioxisome proliferative activator receptor 
NPH                    Insulin Protamine Hagedorn 
GFR                    Glomerular filteration rate 
ESRD                  End Stage Renal Disease 
The A1C             haemoglobin A1C 
SMBG         Self monitoring of blood glucose 
GSP             glycated serum protein 
GSA             glycated serum albumin. 
HPLC:           High performance liquid Chromatography  
 AdA:              adenosine deaminase assay  
UKPDS          United Kingdom Study prospective Diabetes 
ICI                 Institute of continuous improvement  
NICE            National Institute of Clinical Excellence  
ADA            American of drug Association 
FDA            Federal Drug Association  
ACE-I         Angiotensin converting enzyme inhibitors 
ARB           Angiotensin receptor blocker 
HOT            Hypertension Optimal Treatment 
HOPE         Hypertension optimal Practice Evaluation 
Steno-2       Scandanavian  Trial  intensive  Treatmentl of diabetes  is needed  to      
                              be optimized  
 
 
 
 
 
 
 
 
 
 
  
OBJECTIVE: To compare the accuracy of fasting blood glucose, two hour post breakfast 
glucose and three hour post breakfast glucose (FBG, 2hPBG, 3hPBG) in inferring glycemic 
control as judged by glycated hemoglobin (HbA1c); and to evaluate their association with 
diabetic complication. DESIGN: Description of type 2 diabetes glucose profile and Comparative 
cross sectional Study. SETTING: Sudanese population. Patients: 99 People aged 30-70, 55% 
females, with type 2 diabetes on oral therapy. FBG, 2hPBG, 3hPBG were measured three times 
one-week apart; by the end of the month HbA1c was measured. Patients were evaluated for 
clinical evidence of complications; haemoglobin, serum creatinine and ECG were done. MAIN 
OUTCOME MEASURES: Sensitivity, specificity, positive and predictive values. RESULTS: 
Patients control profile was poor in the majority. Correlations among different parameters 
showed FBG to be strongly correlated with HbA1c (r=0.601; P=0.000). 2hPBG correlated 
weakly if at all with HbA1c(r=0.202; p=0.102) but has good prediction of poor control (p = 
0.000). 3hPBG correlation with HbA1c(r=0.547; p=0.000) was less. 2hPBG, 3hPBG correlated 
very well both on single determination and means of values(r=0.912, 
0.900.P=0.000).Correlations with FBG were less r=0.830, 0.841 respectively. Poor correlation 
was shown between level of glycemia and long term diabetic complications except erectile 
dysfunction (P=0.35). Conclusion: Sudanese diabetic should have their postprandial glucose 
measured, in addition to fasting glucose and /or HbA1c. 2 and 3 hour postbreakfast blood 
glucose can be used alternatively. Medications specifically designed at the management of 
postprandial hyperglycemia should be included in the routine treatment of Sudanese diabetics. 
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INTRODUCTION 
Diabetes is a global epidemic that affects more than 150 millions worldwide .Its 
overall prevalence is 2-4% .1, 2Being low 1-3% in the third world, affects  
10-20% of adults in many developed countries3 and as high as 30% in Pima Indians 
population. The WHO stated in 1998 that a 122 % rise in the number of adults with 
diabetes is projected by 2010 to reach 300 million adults worldwide.4Arabs with 
their common genetic background make the thrifty phenotype hypothesis an 
attractive proposition to explain the explosive emergence of diabetes in the Arabs' 
region.5 This is closely related to obesity, ageing and growth of population, 
unhealthy diet and sedentary lifestyle. 
U.K. Prospective Diabetes Study and other clinical trials had clearly demonstrated 
the benefit of good glycemic control in markedly reducing long term 
complications. Measurements of glycemic control had witnessed major changes 
over the years; glycated HbA1c provides an objective measure that predicts 
development of complications. Accumulating evidence had suggested postprandial 
glucose as better tool. 
Diabetes exerts a huge toll in illness, death, loss of quality of life and economic 
consequences at societal and individual levels. Many challenges lie ahead, diabetes 
must be diagnosed earlier and complications must be prevented or treated. New 
and existing medicine and technologies must be used in innovative ways. 
 
 
 
 Definition: 
Diabetes Mellitus is a chronic heterogeneous group of metabolic disorders 
characterized by hyperglycemia due to deficiency or decrease in action of insulin 
or both and increased glucose production.6, 7It is often associated with metabolic 
dysregulation causing changes in multiple organs that imposes tremendous burden 
on patients with diabetes.8  
Historical Background 
Diabetes was described for the first time by ancient Egyptians 3500 years ago. The 
term “diabetes” was put by Aretaeus (81-133 AD), he said “Diabetes is a melting 
down of the flesh and limbs into urine, the patients never stop making water but 
the flow is incessant as if from the opening of the aqueducts 9. 
Later the word mellitus (Honey sweet) was added by Thomas Willis 1675.  
In 1776 Dobson confirmed the presence of excess sugar in urine and blood as 
cause of their sweetness. Claude Bernard in 1857 introduced the concept of excess 
glucose production in diabetes. Messing in1889 described the role of glucose 
production as a cause of diabetes. Insulin was prepared by Bantiry and Best in 
1921, oral medicine waited till 1955 to be marketed, first was tolbutamide. 10 
Thereafter greater insight and discoveries were made.  
EPIDEMIOLOGY 
Diabetes represents the ninth leading cause of hospital admission in Sudan 1.9 %. 
The number of patients had almost doubled in 2000 compared to 1997 (6863 vs. 
3619). 11  
The crude prevalence of diabetes in Sudan was found to be 3.4% (men 3.5 %, 
women 3.4 %).Impaired glucose tolerance was estimated at 2.9%.The highest 
crude prevalence was seen in the northern part (5.5 %) and the lowest in the 
western desert –like parts (1.9%).12The highest prevalence was seen in Danagla 
tribe (8.3 %).13Family history of diabetes and obesity were associated with higher 
rates.12The average hospital death attributed to diabetes over the past four years 
(1997-2000) was 5.89 %. 11 
Traditionally thought to affect individuals older than 40,however type 2 diabetes is 
being recognized increasingly in younger age groups largely associated with 
obesity .It comprised some 30% of new cases of diabetes in second decade of life 
in native Americans14. In China and Japan and Pacific Islands more than 70% of 
diabetic children have type 2 diabetes.15Type 2 diabetes in Japanese schoolchildren 
has increased more than 30 folds over the past 20 years. 14 
Incidence increases with age, 10% of North European aging more than 70 years 
have diabetes.8The reported crude prevalence of type 2 diabetes in Kuwait in 1996 
was 7.6% .It was 15% and 26% for age groups 40-50 and 76 respectively.5 
Diabetes is slightly more common in females (1: 0.97).16,17 50% of cases remain 
undetected.16 African& Hispanic-Americans, Asian, Pacific Islander are highly 
susceptible. 7,14 Arabs are prone to high rates of diabetes ; in 1997 Tunisia reported 
(7-13%) , Kuwait (7.6%) ,Bahrinian age standardized prevalence were  25% ,48% 
,23% in Jaafari , Sunni and Iranian Arab respectively.5 
In the Sudan the crude prevalence fell from 5.5% in Arab predominant region to 
1.9%  in African predominant desert-west part. 12 
Classification of Diabetes18 (Aetiologic ) 
The 1979 classification has been replaced by 1998 with many modifications. It reads:- 
 1. Type 1 diabetes: 
Specified destruction of pancreatic β cells usually with complete insulin deficiency: immune 
mediated or idiopathic. 
2. Type 2 diabetes: * 
Predominantly insulin resistance coupled with a relative insulin deficiency or mainly insulin 
excretion defect associated with insulin resistance.        
3. Other specific types: 
1. Genetic pancreatic cell dysfunction. 
    *MODY1-3 (maturity onset diabetes of the young) 
2.Mitochondrial DNA defect diabetes 
3. Others: 
A. Genetic insulin action defect: Insulin resistance type, Leprechaunism, Rabson Mendehall 
syndrome, lipoatrophic diabetes.etc. 
B. Exocrine pancreas diseases: 
 Pancreatitis, Cystic Fibrosis, Fibrocalculous pancreas, Haemochromatosis, neoplasia 
and trauma/pancreatectomy 
C. Endocrinopathy: Acromegaly, Cushing syndrome, Phaeochromocytoma,       
Hyperthyroidism, Glaucagonoma, Somatostainoma, Aldosteronoma.etc 
D. Drug induced:  
 Corticosteroids, thiazides, beta adrenergic antagonists .etc 
E. Infections: cytomegalovirus, roseola infantum.etc 
F. Unusual forms of immune mediated diabetes: 
    “Stiff-man” syndrome, anti insulin receptor antibodies. 
G. Other genetic syndromes associated with diabetes: 
    Down, Klinefelter, Turner syndromes, Wolfram syndrome, Friedrick’s ataxia,               
Huntington‘s chorea, Laurence-Moon–Biedl syndrome, Myotonic dystrophy, Porphyria, 
Prader –Willi syndrome, and others. 
4. Gestational diabetes mellitus (GDM) * 
#Patients with any form of diabetes may require insulin treatment at some stage of their disease. 
Such use of insulin does not, of itself, classify the patient. 
*Even after presenting in ketoacidosis, these patients can briefly return to normoglycemia 
without requiring continuous therapy (i.e., "honeymoon" remission). 
 
 
Glucose metabolism7,8,,19,20 
Blood glucose levels are precisely regulated in health and rarely stray outside the 
range of 3.5 –7.0 mmol/l (63-126 mg/dl) despite the varying demands of food, 
fasting and exercise. After eating plasma glucose concentrations rise to a peak in 
30-60 minutes and return to basal concentrations or below within 2-3 hours.19,20 
Principal organ of glucose homeostasis is the liver, which stores glucose in the fed 
state as glycogen and releases it in non-fed times to match the rate of glucose 
utilization by peripheral tissues.  The liver produces 90% from the 200 g of glucose 
produced and utilized each day. 7,19,20 
Glucose utilization: 
The brain needs glucose as fuel. 19 Other tissues like muscles or fat use glucose 
electively. The effect of insulin peaks associated with meals is to lower the 
threshold for glucose entry into cells. At other times energy requirements are 
largely met by fatty-acid oxidation.7,19,21  There are many glucose transporters to 
facilitate glucose diffusion like  sodium sensitive SGLT 1,2,3 and GLUT 1,2,3,4,5. 
GLUT4 which is found in muscles &adipose tissues is insulin sensitive.19 In the 
fed state glucose is taken by muscles, liver and adipocytes and stored as glycogen 
and triglyceride. 7,19,21,22  
Insulin: 
Is a 51 polypeptide hormone secreted by the beta cells(IC) from the pancreas as 
proinsulin which is cleaved to insulin and c-peptide. It is the major regulator of 
intermediary metabolism of carbohydrate, protein synthesis and lipogenesis.  
It facilitates the diffusion of glucose into cells and regulates membrane polarization 
and ion transport by regulating Na-K+ATPase. Insulin is secreted in a pulsatile 
pattern with small secretary bursts occurring every 10 minutes superimposed upon 
greater amplitude oscillations every 80-150 minutes.7,19,20  
Meals and other main stimulants induce large -4-5 folds- bursts (vs. basal) of 
insulin that usually last for 2-3 hours before returning to baseline.7,19 Once secreted 
in the portal vein, 50% would be extracted and degraded by the liver ,the 
unextracted re-enters the circulation. Elimination half life is 1.6-3.4 minutes (5.3-
7.8 minutes in diabetics).20 
Insulin is rapidly metabolized in the liver, kidney (80%) and muscles by 
glutathione transhydrogenase. Metabolites appear in the urine.19,20Counter 
regulatory hormones e.g. glucagon, growth hormone and adrenaline shift the 
insulin dose-response curve to the right resulting in greater production and less 
utilization of glucose for a given level of insulin.19,21 
Insulin receptor (IR): 
Is a glycoprotein coded for by the short arm of chromosome 19. It is a dimer with 
two alpha subunits which include the binding sites for insulin, and two β subunits 
which traverse the cell membrane .Binding of insulin activates tyrosine kinase 
initiating the metabolic cascade response. 
 Consequently the GLUT4 glucose transporter migrates to the cell membrane. The 
insulin–receptor complex is then internalized, insulin is degraded by insulin 
protease, and the receptor re-circulates to the cell surface. 7,8,19  
Insulin receptors are widely distributed even in insulin independent human brain 
cells with no difference in affinity to both human and porcine insulin.23 
Pathophysiology and risk factors of type 2 diabetes 
Hyperglycemia is produced by the interplay of relative lack of endogenous insulin, 
insulin resistance and increased production of glucose.7,8,24 This results in 
decreased glucose transport in muscles, elevated hepatic glucose productions and 
increased  fat breakdown.7,24 
The genetics of diabetes type 2 is complex and not fully understood but it is 
polygenic and heterogeneous. Monozygotic twins Concordance is about 100%.25 
 Siblings of patients with type 2 diabetes have  a lifetime risk of almost 40%.8 25% 
of patients have first degree relative with type 2 diabetes.26 Evidence had supported 
the theory of inherited components for both pancreatic β cell failure and insulin 
resistance.24,25 
 Despite extensive studies few genes were identified accounting for a few number 
of cases. Increased expression of genes coding for glucose-6-phosphatase and 12-
lipoxygenase were demonstrated.26Recent evidence had implicated overexpression 
of glucose-6-phosphatase gene in the beta-cell dysfunction that occurs in ob/ob 
mice.26Other genes involved those coding for insulin receptor (AD),glucagon 
receptor,Esokinase.7,24,25 
Monogenic diabetes accounts for less than 5%.7,25 Best studied is Maturity Onset 
Diabetes of the Young (MODY) which is autosomal and dominantly 
inherited(AD). It results from mutations in at least three different genes on 
chromosomes 20 (MODY 1), 7 (MODY 2–glucokinase5), and 12 (MODY 3).25,26  
Monogenic diabetes also includes the maternally inherited diabetes shown to be 
associated with mitochondrial DNA mutation A to G 3243. It accounts for 1% of 
diabetes, associated with deafness and myopathy. 27  
Insulin resistance: 
Patients with type 2 diabetes retain 50% of βcell mass at autopsy.8In established 
type 2 diabetes insulin mediated suppression of hepatic glucose production  and 
tissue glucose uptake are impaired. Glucose clamp studies in patients with type 
2 diabetes showed a defect in insulin action post insulin membrane receptor.7,28 
Defects in intracellular oxidation and storage of glucose (as glycogen) have been 
identified.28 Groop et al showed that insulin resistance is confined to those with 
microalbuminuria and hypertension.29In non-obese blacks with type 2 diabetes 
both insulin resistant and sensitive subtypes of diabetes have been identified. 
Abdominal fat deposits correlated with the resistant group.30Recent evidence 
suggested elevated free fatty acids (NEFA) as a driving force behind insulin 
resistance and even βcell dysfunction. 24,31 
Lipotoxicity& Glucotoxicity:  
Increased circulating free fatty acids or increased cellular fat content have 
diabetogenic effect, reduction greatly improved  glycemia.32Increased levels of 
plasma glucose lead to altered level of intracellular glucose.  
Progressive hyperglycemia was associated with worsening of overall metabolic 
condition.32 Hawkins et al showed the contribution of hyperglycemia and/or 
hyperlipidemia to the impaired effectiveness in regulating glucose fluxes in type 2 
diabetes. Short term normalization of glucose might break the vicious cycle .33 
Environmental factors: 
In Utero Environment Effects: 
 Many studies showed that persons with low weights at birth or at one year had 
higher rates of type 2 diabetes later in life .This fetal origin hypothesis showed that 
diabetes  and stroke ,coronary heart disease, hypertension were results of 
adaptations made by the fetus in response to malnutrition in utero.34,35Insulin 
resistance may explain the risk for these disorders.35However Stanner SA, Bulmer 
K and associates demonstrated that intrauterine malnutrition wasn't associated with 
glucose intolerance in adulthood but with endothelial dysfunction and stronger 
influence of obesity on blood pressure.36Sobngwi E et al showed the increased 
occurrence of impaired glucose tolerance and defective insulin secretion in adults 
who had been exposed to diabetic environment in utero.37 
Thrifty phenotype hypothesis: 
Poor nutrition in fetal and infant life is detrimental to the development and function 
of beta cells and insulin sensitive tissues, leading to insulin resistance under the 
stress of obesity. It proposes that defective insulin action in utero results in 
decreased fetal growth as conservation mechanism, but at the cost of development 
of obesity –induced diabetes in later childhood and adulthood. 5,7,24,35 
Obesity: 
Obesity is present in 80% of patients with type 2 diabetes.8 It is associated with 
acquired insulin resistance. Compensatory hyperinsulinemia in obese patients' 
down regulates membrane insulin receptors but the maximal response to insulin is 
preserved.28  
Upper body (android) obesity particularly visceral fat deposition (indicated by high 
waist: hip ratio WHR=0.9) is more closely associated with glucose intolerance and 
other features of insulin resistance syndrome than the lower body (gynaecoid 
WHR=0.7) obesity. 38 
Calculations suggested that subjects who are 50% overweight have12 folds 
increased risk for diabetes.24Populations with high prevalence of  type 2 diabetes 
like Pima Indians , Mexican American , South Asians are predisposed to 
abdominal obesity.39Acausal relation between leptin coded for by ob gene, and 
insulin sensitivity has been suggested. 40 
Smoking and alcohol: 
Current smoking (25 or more cigarettes daily) doubles the risk of diabetes among a 
healthy men population whereas moderate alcohol consumption significantly 
decreases the risk of diabetes. 41 
Inflammatory markers: 
Maria Anes showed that inflammatory markers; raised white cell count, sialic acid 
and orosomucoid were associated with the development of diabetes in middle-aged 
adults. They probably reflect the pathogenesis of type 2 diabetes. 42 
Islet amyloidosis: 
Islet amyloidal deposits are derived from islet amyloid polypeptide (IAPP) which 
is co-secreted with insulin. They were seen in more than 90% of diabetics, greatest 
in those who require insulin.It has been implicated in beta cell cytotoxicity 
(reduction in cell mass) and interference with glucose and hormone transport.7,8  
Proposed mechanisms are extracellular and intracellular deposition, increased 
expression of apoptosis related genes e.g. p53, p21; and oxidative stress .Its 
potential therapeutic targets include medications to inhibit IAPP production and to 
prevent fibril deposition. 43 
In conclusion type 2 diabetes occurs when a diabetogenic environmental event like 
westernized lifestyle mainly physical inactivity, overweight , high energy yielding 
dietary habit and obesity superimpose upon genetically programmed defect of beta 
cell failure and insulin resistance. 
Clinical Presentation 
Type 2 diabetes represents 90% of the diabetics; it is 10 times more common than 
type 1.24  
The diagnosis of diabetes is readily entertained when classic symptoms are present: 
polyuria, polydipsia (excessive thirst), weight loss and lack of energy. Other 
symptoms that may suggest hyperglycemia include blurred vision and lower 
extremity paraesthesia.7,8,24  
In many cases complications are the presenting features. They include   infections 
like recurrent boils and tuberculosis16,44 ,hyperglycemia as diabetic ketoacidosis or 
hyperosmolar non-ketotic coma.8,16,17,44 Long term complications include : 
microvascular: diabetic retinopathy, neuropathy and nephropathy. 
 Macrovascular diseases (CVD) which include: Coronary heart disease, Carotid 
and peripheral ischaemia leading to myocardial ischaemia (CHD), TIA/stroke and 
limb amputation. 
 High blood pressure is common (40%)17,18,44 and should warrant screening.16Most 
patients are however asymptomatic for a decade and could only be detected on 
routine screening of urine or blood.7,8,16,24,45 
Physical Examination: 
Should emphasize on measuring the weight, height and blood pressure. Careful 
cardiovascular, neurological examination including fundi, foot and peripheral 
pulses and skin examination for evidence of complications. 7,8,16,24,45 
The dysmetabolic syndrome: 
Previously known as Syndrome X.46 It is an often finding in type 2 diabetes and is 
due to insulin resistance. 47Diabetes is only the tip of the iceberg. 
Criteria for diagnosis: Any three of the following 7,24,46,47: 
-Abdominal obesity   : Waist to hip ratio (WHR) >1.0 in Females, > 0.8 in Males. 
-Lipid disorders: Triglycerides (TG) >150, 
 high density lipoprotein (HDL)< 40 mg/dl  
-Blood pressure   :          >180/85mmHg. 
-Fasting blood glucose :  >110mg/dl 
Diabetic Complications 
UKPDS had shown that 50% of patients with type 2 diabetes had already one or 
more complications by the time of diagnosis.48 Diagnosis of diabetes immediately 
increases the risk of developing various clinical complications that are largely 
irreversible and result from both macrovascular and microvascular 
derangements.8,16,38,49 
Diabetes is progressive. When followed over 6 years up to 18% had developed one 
or more diabetes clinical end point.50 
Diabetic complications can be divided into: 
1. Acute complications. 
2. Long term complications. 
Acute complications: 
1/Diabetes keto acidosis (DKA): 
DKA results from absolute insulin deficiency or insulin inefficacy with elevated 
levels of counter regulatory hormones.7,8 
Although classically associated with  type 1 , high proportion (39%) of DKA in 
non-white adults occurs in persons with type 2 diabetes especially in those with 
previously undiagnosed.5158 % of DKA presenting to Khartoum (1997-1998) were 
type 2. Poor compliance precipitated half of cases. 52 
When treating patients with hyperglycemia, it is important to consider the 
possibilities of both acidosis and hyperosmolarity, no matter what the age or 
presumed type of diabetes. 53 
2/Hypoglycemia: 
Low blood sugar is a common problem in diabetics. It is crucial to consider 
hypoglycemia in all patients with neurological symptoms because outcome 
depends on its duration. A recent study of hospitalized patients revealed an overt 
incidence of hypoglycemia of 1.2%; of these 45% were diabetics.53 Type 2 patients 
have preserved warning of hypoglycemia till late in life.24 
3/ Hyperosmolar non –ketotic coma (HONK): 
It is a non acidotic state of a generally more marked hyperglycemia with 
significantly increased plasma osmolarity.7,8 ,38 
4/Lactic Acidosis:  
 A rarity that occurs in the setting of collapse or severe infection, renal, hepatic 
decompensation or hypoxia particularly when the patient is on metformin.38  
Long term complications: 
Cardiovascular complications (CVD) 
The most costly complication of diabetes up to 80% of adult diabetic have clinical 
or subclinical coronary heart disease at any given point in time. 45  75-86 % of all 
deaths in adults with type 2 diabetes are due to macrovascular events.45,54,55The 
relative risk compared to non diabetic is 2-5 folds for CHD and myocardial 
infarction(MI), 2-3 for stroke and 40 folds for amputation . 
Cardiovascular risk factors in diabetes are the same as in non-diabetic in addition 
to hyperglycemia, prothrombotic diabetic state and microalbuminuria.56 Also there 
is an increase in heart failure (diabetic cardiomyopathy) caused by ischaemia, high 
blood pressure and myocardial cell dysfunction due to chronic hyperglycemia.7,56 
Diabetic eye 
Eye complications in diabetes include cataract, glaucoma and retinopathy, retinal 
vein thrombosis, optic atrophy.7,8,16,38 Diabetes is a leading cause of blindness in 
working age adults in US. National Eye Institute estimates that 90% of lost vision 
is preventable. 57   
The relative risk of retinopathy compared to non diabetic is 20.57 Prevalence of 
retinopathy varies with race, age and duration of diabetes.24,45Abnormalities start 
by changes in leukocytes adhesion and alteration in retinal blood flow. 
Microvascular defects: retinal hemorrhages, microaneurysm and intraretinal 
microvascular changes supervene.57 Progressive non-perfusion of retinal capillaries 
results in retinal ischemia and increase in growth factors leading to abnormal 
proliferation of new vessels.7,8,38,57 
These vessels are fragile, bleed easily and undergo scarring and fibrosis leading to 
traction on the retina, retinal detachment, and severe visual loss. At any stage 
retinal vessels may become abnormally permeable resulting in transudation of 
blood serum components into the retina and the macula (edema and exudates). 57,58  
Knock mice model study suggested that insulin signaling in vascular endothelial 
cells of the retina may play an important role in the progression of diabetic 
retinopathy and expression of angiogenic factors (insulin receptor role). 
59Hypertension is an independent risk factor for diabetic retinopathy.57 
Diabetic nephropathy: 
Diabetes is the leading cause of End Stage Renal Disease (ESRD). 49 In US about 
28.000 patients with diabetes develop ESRD every year.24,45Most future ESRD is 
probably preventable. 49Relative risk compared to non diabetic is 25.24,45 
Genetic predisposition to hypertension and persistent elevation of GFR predicts an 
increased risk of nephropathy.60The risk is 3-6 folds higher in African-American, 
Latinos and Native Americans. 60-61 
Hyperglycemia in the diabetic range can cause microalbuminuria. Controlled trials 
demonstrated that intensive glucose lowering prevents the onset and progression of 
microalbuminuria with a continuous graded relationship between level of glycemia 
and risk of abnormal urinary albumin excretion (UAER). 62 
Mechanisms of glucose related albuminuria include glycation of basement 
membrane proteins with loss of charge selectivity and glomerular hyperperfusion 
and hyperfiltration.11-67% of patients progress to overt proteinuria over 5-15 years 
of follow up.60,62Progression to ESRD varies individually.49  
Heterogeneity in progression of microalbuminuria is determined (in addition to 
variation in glycemia) by baseline UAER, cigarette smoking, levels of blood 
pressure, serum lipids and genetic effect, and diabetic retinopathy.60,61Other factors 
which don't seem to act as risk factors include obesity, known duration of diabetes, 
arterial blood pressure, serum creatinine concentration and pre-existing coronary 
heart disease.60 Diabetes is the cause of kidney failure in 42% of patients on 
dialysis. 62 
 
 
 
 
 
 
 
 
Neuropathy 
One common and early complication of diabetes.7,8,16,38 The commonest form is a 
diffuse progressive polyneuropathy affecting mainly the feet. It is predominantly 
sensory, often asymptomatic, and affects 40-50% of all patients with diabetes.7,49 
Other forms include polyradiculopathy which presents with root pain and motor 
weakness. Lumbar plexus or femoral nerve affection causes pain and weakness in 
the hip and thigh (diabetic amyotrophy). Also occur are polycranioneuropathy and 
monocranioneuropathy commonly 3rd, 4th, 6th cranial nerves, mononeuritis 
multiplex and Bell's palsy. Autonomic neuropathy is common. It manifests as 
gastropathy, oesophageal dysfunction&cytopathy. Erectile dysfunction is a 
common early sign of neuropathy.7,8,16,24,38,49,63 
Diabetic foot: 
Diabetes is the leading cause of non-traumatic lower extremity amputation in the 
US with 15-40 folds increase in risk compared to the nondiabetic population .24,45 
Each year 67.000 limbs are lost secondary to diabetic vasculopathy and 
neuropathy.45,49 15% of diabetics develop foot ulcer. 49  
Risk factors include duration more than 10 years, male gender, smoking, peripheral 
neuropathy, vasculopathy and poor glycaemia .Every 2% increase in HBA1c 
increases the risk of ulcer by 1.6% and leg amputation by 1.5 times.7 
Mortality: 
Diabetes is the fourth leading cause of death in US. It doubles the annual mortality 
compared to non diabetic (5.4%).24,45,54 Life expectancy of a diabetic is decreased 
by 5-10 years. 54 
Laboratory evaluation: 
♦ Urine tests: 
To evaluate for ketones, glucose.7,8,38 Double void technique ensues that the 
specimen being tested reflects the plasma of the time.16,38 The patient should empty 
the bladder, discard the specimen and a further one passed 10-15 minutes later is 
collected and tested.1,16,38Urine collected 1-2 hours after meal will recognize more 
of milder cases than overnight fasting sample.16 
Blood tests for glucose: 
Normal range (reference range): 19,38 
• Fasting  3.5-5.5 mmol/L(74-106mg/dl)64 
• Postprandial  up to 8.7 mmol/L. 
The biological variation is 7.9% and the critical difference is 24.5%.The absolute 
value of critical difference at upper reference limit is 26mg/dl. Glucose 
homeostasis varies with age, sex, time of the day and menstrual cycle. 64,66Fasting 
blood glucose increases 2mg/dl per decade after the age 30, 1 hour postprandial 
increases by 10 mg/dl and 2 hours postprandial by up to 100mg/dl plus age in 
years after the age of 40. 65 
Plasma glucose is determined in a grey top (Sodium fluoride) tube which inhibits 
red cells metabolism.24 Serum glucose measurements give 15% lower results than 
plasma.24,66 
 
 
 
Definition of Diabetes: 24,38,45,66 
  Normal fasting plasma sugar (FPS) less than 110mg/dl (6.1mmol/l) 
Impaired fasting glucose (IFG): Fasting plasma glucose greater than 110mg/dl and 
less than 126mg/dl. 
Impaired glucose tolerance (IGT):2-hour plasma glucose greater than or equal 
to 140mg/dl and less than 200mg/dl 
Diagnostic Criteria of Diabetes mellitus: 7,8,16,18,38 
♦ Classic symptoms of diabetes plus casual blood glucose greater than 200 
mg /dl (11 mmol /L) measured at any time without attention to food. 
♦ Fasting blood glucose greater than 126 mg/dl (7.0 mmol/L), no food 
(caloric) intake for more than 8 hours. 
♦ Blood glucose 2 hours after oral glucose loading done with 75g of glucose 
in water, greater than 200 mg/dl (11 mmol/l). 
In the absence of unequivocal hyperglycemia associated with acute metabolic 
decompenstaions, the results should be confirmed by repeat testing on a 
different day with any of the three methods. 
Oral glucose tolerance test (OGT): 16,66 Conventional OGT should no longer be 
used except for borderline cases or diagnosis of gestational diabetes. 
Other laboratory tests include: urine for microalbuminuria (2 out of 3 tests 
>300mg/24hours) or proteinuria and Cultures. Serum creatinine, lipid profile, 
HbA1c, insulin and C peptide levels. Auto antibodies (ICA, GAD65, tyrosine-
phosphatase-like auto antigen IA). 7,8,24,38 
 
Differentiation between type 1 and type 2 diabetes: 
Type 2 diabetes can be differentiated from type 1 by the presence of ethnicity, 
family or gestational history of diabetes, obesity and acanthosis negricans.24,67 
Greater than 10% improvement in glucose levels in response to oral drugs plus the 
occurrence of  characteristic diabetes dyslipidemia (high TG) would further aid in 
the diagnosis. Usually there is no need for measuring C peptide, auto antibodies 
GAD65, ICA.7,24,67However the gold standard tool is “glucose clamp” procedure 
which is used only in research settings. 28 Clinicians can make an educated clue to 
which type of diabetes clinically and by using simple tests. 67 
Screening: 
Should be offered to the high risk groups. They entail those who have  first degree 
relative with type 2 diabetes, females with a history of big babies (4kg), gestational 
diabetes or polycystic ovary syndrome. And hypertensive individuals plus  those 
with high lipids.18, 24,38,45Screening by blood glucose measurements perform more 
favorably than urinary glucose or HbA1c, and measuring postprandial glucose 
levels may have advantages over fasting levels. 24,45,68 
The optimal interval for screening is unknown,even though periodic, targeted, and 
opportunistic screening within the existing health care system seems to offer the 
greatest yield and likelihood of appropriate follow-up and treatment. 68 
 
 
 
 
Management 
The direct and indirect cost of managing diabetes in US is 105 billions annually, 
majority spent on hospital care.69The American Association of Clinical 
Endocrinologists (AACE) published a system of intensive self management of 
diabetes .It entails three phases: Initially a customized-therapeutic approach, then 
the follow up phase .Thence ongoing assessment of complications, re-education of 
patient and encouragement to maintain enthusiasm for the difficult task of 
intensively managing blood glucose. 70 
Special talents of diabetes education, nutritionist or hospital diabetes center would 
be helpful. Educational handouts, appropriate web site references should be 
provided. Patients should be encouraged to purchase home glucose monitor. 45,69,70 
Diet and Exercise 
It does work initially but as time goes on, patients start to sneak back 
 into their customary diet .71 Best regimen is a relatively high fibre, high 
carbohydrate, low fat and low protein, with plenty of vegetables. 72  
Medications: 
Physician should not wait for the effect of exercise and diet as there is no mild or 
severe diabetes, all patient should be offered best of care available.7,8,16,24,38,45 
Sulfonylurea :(SU) 
Derivatives of sulfonamide rediscovered by Frank 1952.73The most experienced 
oral hypoglycemic drug.74They directly stimulate insulin release by binding to a 
receptor (SUR) on the K+-ATP channel in the βcell membrane. This closes the 
channel causing depolarization and insulin release.74,75 
Members of this class have similar efficacy but different 
pharmacokinetics.8,24,76They were introduced in generations; the 1st are 
Acetohexamide, tolbutamide &glibenclamide. The 2nd are Gliclazide ,glyburide, 
Glipizide. 74 
Prevalence of primary failure may be as low as 15%73 but secondary failure occurs 
in 7-10% of patients every year as βcell function declines.76 Most patients require 
additional medication after about five years.69,74 Few side effects are seen other 
than hypoglycemia  which occurs more with glyburide commonly in renal failure& 
hepatic diseases.69,73,74-76 Despite earlier concerns UKPDS  proved that SU didn't 
increase CVD  events . 48 
Biguanides: 
The active ingredient in Galega officinalis (Goat’s rue) herb, guanidine had been 
used to synthesize metformin in 1950’s.73-74 Metformin is the only available drug. 
It reduces gluconeogensis and glycogenlysis69,74-75by acting primarily on the liver, 
adipocytes and myocytes.It increases insulin-stimulated glucose uptake by 10-
40%. Efficacy is  similar to SU with no weight gain.24,6973-75It significantly reduces 
TG, LDL and increases HDL.74 The main side effects are metallic taste, GI upset. 
Lactic acidosis is rare (3/100,000 per year).It mainly occurs in renal impairment, 
hypoxia, severe heart failure and decompensated liver states.24,73-75UKPDS 
suggested a preferential benefit against macrovascular events in obese.34 It is the 
ideal choice for obese diabetic. 34 ,77 
Thiazolidinediones (TZD): 
Available are Pigolitazone& rosiglitazone. The drug interacts with the nuclear 
perioxisome proliferative activator receptor (PPAR) forming a complex that 
regulates genes involved in lipid metabolism in fat and muscles. This leads to 
reduction of release of NEFA from adipocytes with reduction in insulin 
resistance& hepatic glucose output. 74-76 They positivey affect lipids, high blood 
pressure, reduce vascular inflammation and vascular smooth muscle 
proliferation.69,74,76 The Main side effects are oedema, weight gain and 
exacerbation of heart failure. Liver toxicity is rare than with troglitazone. 45,69,73-74 
Alpha glucosidase inhibitors: 
Available are acarbose , miglitol. They reduce and delay carbohydrate absorption 
by competitively inhibiting disaccharidases in the intestinal brush border and 
pancreatic alpha amylase. They are used in obese with poor diabetes control. GI 
upset limited their uses. 69,74,75-76 
Insulinotropic short acting secretagogues(Non SU) 
Meglitinide analogues like repaglinide  , nateglinide,and mitiglinide 
They have similar action to SU but more potent, rapid onset and shorter duration of 
action and less hypoglycemia.78Allow premeal dosing and better control of 
postprandial glucose excursion. 24,69,74,76,78 
Insulin: 
Insulin is the last resort for type 2 diabetes.79 Recombinantly produced. It is 
indicated in severe diabetic complications, severe infections, in major surgery and 
at gestation, as bridge to treat glucotoxicity.20,69,76 Insulin types are Rapid acting,  
basal insulin intermediate (NPH:Neutral Protamine Hagedorn, 
 IZS :insulin  zinc suspension) and premixtures .79Side effects include 
hypoglycemia, skin allergy ,lipoatrophy-hypertrophy& insulin resistance .20,76,79 
Insulin analogues: are chemically modified insulins: ULtra-rapid are insulin lispro, 
Aspart. They are more rapidly absorbed from subcutaneous tissues(5 minutes) and 
remain active for shorter duration than soluble human insulin.45,73,76,79 Longer 
acting insulin glargine (di-arginyl insulin analogue ,Lantus) which remains 
essentially unchanged for 24 hours, and is unaffected by the site of injection.45,69,79  
Future Therapy: 
Imidazole derivatives S-21663: glucose independant secretagogue.75 
Morpholinoguanidine BTS 67582: stimulates insulin secretion in site separate 
form SUR.  
Non-TZD insulin sensitizers: G1262570X (GG570) and D chiroinositol. 74-75 
GLP-1 (7-36 amide): a natural enteric incretin hormone that improves pancreatic 
beta-cell and alpha-cell sensitivity to glucose80. 
Organic vanadium compounds: enhance insulin biosynthesis and secretion. 
Modern methods for insulin delivery: 
Innovative ways for insulin administrations include:  
Inhaled Insulins which have excellent control, safety and patient acceptance. It 
will be stable at room temperature for up to 2 years. Systems available are 
inhaled therapeutic system and hand hold inhalation device. 75,81  
Oral insulin preparations are already being used in phase 3 clinical trials with 
reports of good effectiveness and accurate dose titration.75 
Infusion insulin pumps provide near physiological control of glucose.7,8,38 
 
Rational drug approach to type 2 diabetes: 
The first modality is lifestyle adjustments aimed at improving endogenous insulin 
sensitivity or insulin effect. This can be achieved by increased physical activity and 
bodyweight reduction with diet and behavioural modification, and the use of 
pharmacological agents or surgery.24,45,69,82Secondly is to increase availability of 
insulin by giving exogenous insulin, insulin analogues, sulfonylurea and insulin 
secretagogues (repaglinide).The association between hyperinsulinaemia and 
premature atherosclerosis is still a debatable question.82,83 The third modality 
consists of agents such as biguanides and glitazones which enhance insulin 
sensitivity, or agents that decrease insulin requirements like the alpha-glucosidase 
inhibitors. Therapy should be individualized based on the degree of 
hyperglycemia, hyperinsulinaemia or insulin deficiency. Efficacy, safety, 
affordability and ease of administration should all be considered.82 
HYPERGLYCEMIA 
The diabetes control &complications trial(DCCT) 84conclusively proved that better 
glycemic control mitigates the ravages of microvascular diabetic complications in 
type 1 diabetes. Kumamoto study85 on comparing intensive treatment with insulin 
against conventional therapy in type 2 diabetes showed less microangiopathy in the 
former. Both DCCT& Kumamoto showed reduced incidence of microvascular 
complications by 50-70 % and demonstrated a non-significant trend towards 
reduction of macrovascular complications.76,84,85 
UKPDS3348 compared conventional(diet) and intensive glycemic 
control(sulfonylurea, insulin, metformin ),net reduction of 0.9% in HBA1c had 
been translated into 12% fewer diabetes end points, 25% reduction in 
microvascular  events (p=0.0099),incidence of myocardial infarction was reduced 
by 17% but with borderline significance.48 Metformin treated group had less 
mortality .77 Any abnormal HBA1c value is considered too high. 76 The cut off 
point for optimal glycemia management was 7%HBA1c.1,48,76,77,84,85 
UKPDS therapeutic decisions were made on FBG values that could explain at least 
partially the lack of effect on macrovascular events as recently accumulating data 
suggested beneficial effects with better control of non-fasting glucose excursions.1 
POSTPRANDIAL BLOOD GLUCOSE CONTROL 
 Nowadays little of the day is spent fasting and most of the times in postprandial or 
postabsorptive state. Wide fluctuations in plasma glucose levels may occur 
throughout the day with high values 1 to 2 hours after meal, so it is not surprising  
that postprandial hyperglycemia is a greater contributor to blood glucose control 
than fasting.78 Jovanovic et al reported that the postprandial glucose at one hour is 
the best predictor of HBA1c in patients with well–controlled type 2 diabetes86. 
 Avignon A and associates showed that non-fasting plasma :2h postprandial and 
sustained postprandial (5 h) post lunch glucose levels are better predictor of overall 
glycemic control than fasting glucose. 87This was backed by a French study which 
showed stronger correlation between 2h post breakfast and HBA1c.88  
Physiological background: 
Pulsatile insulin secretion optimizes its action20.It is secreted in two phases: 
Early- phase insulin release: 
 Is a short and small burst released on food intake or increase in glucose plasma 
concentration, in the first 10 minutes.20,89It represents the release of small pool of 
preformed and readily accessible insulin in secretary vesicles. This burst preempts 
and decreases the postprandial glucose elevation in the blood. 20,78,89 
 Late- phase insulin release: 
More sustained release of insulin .It relies on mobilizing stored pool and/or de 
novo insulin synthesis.78,79,89 
The initial insulin release is lost early in type 2 diabetes and is an excellent 
predictor of both types of diabetes.89,90 Loss or attenuation of early-phase insulin 
release after a meal results in inadequate insulin suppression of hepatic glucose 
production. 78,89 Initially extensive stimulation of the second phase ensues which 
leads to insulin resistance through down-regulation of the  insulin post-receptors 
pathways on muscles and fat cells. 89 Hence loss of early insulin burst results 
in postprandial hyperglycemia, insulin resistance and progressive loss of insulin-
producing cell in both types of diabetes. 78,89,91,92 
The effect of postprandial glucose on microvascular complications 
High blood glucose levels ( postmeals) lead to increased synthesis of 
diacylglycerol, which jointly with intracellular calcium  activate protein kinaseC 
.The result is impaired contraction of smooth muscles(pericytes),increased 
production of basement membrane material ,and enhanced cell proliferation and 
capillary permeability.93 
Activation of protein C, endothelial dysfunction and increased expression of 
vasoconstrictor endothelin could be responsible for microvascular complications 
that may be developing in the early stages of diabetes. 89,91,94Data from national 
health and nutrition examination survey showed that 2hour postprandial glucose 
levels of 194 mg/dl had resulted in a threefold increase in retinopathy despite 
normal fasting blood glucose levels.18Similar incidences were reported in studies 
of Pima Indian and Egyptian populations. Mohan et al reported the association of 
high postprandial glucose with diabetic nephropathy.89Beghi et al showed its 
association with increased the prevalence of diabetic neuropathy. 92 
 
 
 
 
 
Postprandial glucose and Macrovascular Complications: 
Glycemic threshold for developing macrovascular complications is lower than that 
for microvascualr.46,89High postprandial blood glucose levels are associated with 
postprandial hyperinsulinemia, atherogenic lipids which heightened the occurrence 
of CHD.89,90 
 Postprandial glucose stimulates platelet aggregation and results in protein and 
cellular glycosylation. Glycosylated LDL particles are more easily oxidized, taken 
up by macrophages through scavenger system with resultant athersclerotic 
plague89-92.Glycosylated HDL is less efficient in transporting cholestrol back to the 
liver than the normal HDL. In addition formation of advanced glycosylated end 
products in the chollagen of the vessel wall may directly stimulate or accelerate the 
atherosclerotic process.92It also stimulates free radicals, plasminogen activator 
inhibitor and endothelial dysfunction. Control of postprandial glycemia reverses 
this hypercoagulable state. 89,94-95 
The Honolulu Heart Study found that the incidence of CHD was twice as high in 
patients with postprandial blood glucose levels between 157-189 mg/dl as in those 
with levels < 140mg/dl. The incidence of sudden death was doubled with levels> 
151mg/dl. 89 The Whitehall study of British male civil servants showed that 2h 
postprandial glucose levels of >196 mg/dl were associated with two fold increase 
mortality from CHD. The Islington Diabetes Survey reported double major CHD 
events when 2h postprandial was 120-180mg/dl (17%) as compared to 
 levels < 120mg/dl. 89-92 
   This had also been shown in the Paris Prospective Study.96 Hooran study 
documented that 2h postprandial glucose value was an independent risk factor for 
peripheral vascular disease.97The Oslo study demonstrated that nonfasting glucose 
levels were predictors of fatal stroke in diabetic patients, risk increasing by 13% 
for each 18mg/dl elevations in postprandial glucose.   
The Diabetes Intervention Study reported that postprandial not fasting 
hyperglycemia was an independent risk factor for myocardial infarction 
and cardiac death. The Helsinki Policemen Study revealed an independent 
association between fatal and nonfatal CHD and I h and 2hour postprandial insulin 
levels than that with fasting glucose. 98-99 
When compared ladies with gestational diabetes with controlled postprandial 
glucose had lower HBA1c, lower birth weight of babies, less neonatal 
hypoglycemia and less caesarean section than preprandial controlled group. Combs 
et al, Demarini et al demonstrated higher incidence of macrosomia & neonatal 
hypoglycemia with high postprandial glucose.89,100 Consequently the ADA 
(American Diabetes Association) now recommends monitoring both fasting and 
1hour plasma serum glucose levels during pregnancy.101 
Control of Postprandial hyperglycemia 
Postprandial hyperglycemic control is important  in avoiding diabetic 
complications, lowering insulin resistance ,restoring normal insulin secretion, and 
avoiding complications in the offspring's of women with diabetes.89,100 Methods 
that lower both fasting and postprandial glucose levels are recommended. 
Oral basal-bolus therapy: 89,90,93 
 Patients with type 2 diabetes who require none or just an evening injection 
intermediate insulin to control the fasting glucose level, an oral agent capable of 
stimulating an insulin release sufficient to cover the meal or  delay the absorption 
of glucose from intestine (bolus agent)should be used. In conjunction with oral 
agents that lower insulin resistance, decrease hepatic glucose production, or 
stimulate insulin production (basal agents). 
Injection basal-bolus therapy: Type 2 diabetics who take insulin, need fast-acting 
lispro-like insulin as bolus therapy, even if they have some preserved endogenous 
production because they lack the first- phase insulin release.102,103 
Basal agents include glitazones, metformin, long acting sulfonylureas, 
intermediate and long acting insulins.78,89-92Bolus drugs: target postprandial 
hyperglycemia preventing hyperinsulinemia, postprandial hypoglycemia and 
weight gain.They include: acarbose, miglitol, repaglinide, lispro-like insulin and 
possibly glimepiride. 78,89-92 
New agents that stimulate short-lived insulin release: 
D-phenylalanine derivative e.g nateglinide enhances insulin release in the presence 
of high glucose levels.78,89 Other group include amylin analogue pramlintide, 
glucagons-like insulinotropic polypeptide(GLIP),they slow gastric emptying and 
suppress glucagons production. Pramlintide replenishes glycogen stores ; GLIP 
increases insulin production in response to a meal. It is easier to achieve the long 
term HBA1c goal <7% using basal-bolus therapy because the biggest contributor is 
the postprandial glucose.78,89-92 
Monitoring Glycemic Control        
The contemporary management of diabetes mellitus is based principally on 
frequent determinations of glycemic control via many methods: 
Self monitoring of blood glucose (SMBG) 
Implies frequent measurements of capillary blood glucose levels by diabetics. 
Blood is obtained by finger prick method and glucose measured with reagent strip 
or meter.104 
For Oft- used fingers, stable patients should take few days off to let the fingers 
heal. Sites with fewer nerve endings like forearm can be used with newer devices, 
but if the patient prespires results are unreliable.46Results may be different from 
finger tip, in which changes in glucose after meal would be detected before 
forearm or thigh. 105 
Veterans Affairs recommend that patients with stable type 2 on oral agents or diet 
perform SMBG twice weekly. Meier JL et al had shown that decreasing the 
frequency of SMBG (0.7strips/ patient /day), resulted in substantial cost saving 
(6.37USD/ patient/ month) without affecting glycemic control.106 Similar results 
were shown in a cohort of 421 with paired GHbA1c data .106 In a review by Faas et 
al of studies on SMBG 1976-96 only one positive conclusion regarding its efficacy 
was found.107 
3. Non –invasive blood glucose monitoring 
Two devices have been approved by FDA: 
1. Minimed (Glucowatch): Uses intophoresis to assess glucose in interstitial fluids  
2. Uses indwelling subcutaneous catheter to monitor interstitial fluid glucose  
Both devices utilize immobilized glucose oxidase to generate electrons in response 
to changing glucose levels.7 These meters  report the value  15 minutes delayed 
from serum level allowing just three readings per hour. They need to be calibrated 
regularly.7,38 
Metzger el al concluded that in real-life setting the accuracy of data provided by 
the Minimed may be less than expected and should be confirmed by independent 
means before clinical decisions are made.108                   
3. Intensive glucose monitoring: 
Some patients with perfect HbA1c or normal FBG develop complications. They 
are likely to have unstable diurnal variation with frequent excursions of high blood 
glucose at night. Unger recommended a 3-day continuous glucose monitoring; 
results showed that glucose levels were greater than 200mg/dl for many hours each 
day in the studied group.46The Minimed glucose sensor allows continuous 72-
hours glucose monitoring and represents a potentially important tool to improve 
the management of diabetes.46  
Long Term Monitoring 
1. Glycosylated Haemoglobin 
Glycated Hb (GHb) is derived from HbA, the major component of adult 
haemoglobin, which also consists of small amount of HbA2 and a trace of Hb F. 
Formation of GHb begins during erythropoiesis and continues through the 120 day 
lifespan of the red blood cells.7,16,38  
It is a post translational modification of haemoglobin. Non enzymatic reaction 
between free aldehyde group of glucose and the unprotonated form of free amino 
acid group of HbA. A labile aldimidine form is generated in the first fast reaction, 
then partially converted into a stable ketonamine form via amadoni 
arrangement.7,16,38,109 
There are various subfractions forms of glycated HbA including HbA1a, HbA1b 
and HbA1c. HbA1c is the most abundant form. Increased amount of HbA1c had 
been found in the serum of diabetics. 16,24  
Since the formation of glycated Hb is irreversible and the level in the red cells 
depends on the concentration of blood glucose, a single HbA1c determination 
reflects the average glucose concentration for the preceding 8-12 weeks.7,48 
Glycated haemoglobin analysis:  
Many tests to measure glycated haemoglobin are available. It is also desirable that 
all laboratories performing A1C testing participate in the College of American 
Pathologists proficiency testing survey for A1C testing started in mid-1996, which 
uses whole-blood specimens104. 
 Two commonly used tests are:- 
-High performance liquid Chromatography (HPLC):  
Is the most accurate method for estimating glycated HbA1c.7,38 
-The Kit method: 
 Is based on the affinity the boronated groups have for cis-diol structures found in 
glycated protein. Glycated proteins are eluted from boronated columns and their 
absorbance determined on spectrometer.7,38,110 Normal values are 4-6% in 
nondiabetic.24,45 
For GHbA1 %: Over treatment is the level less than 6%,very good control is  
6-8% &Good control is 8-9.5%.During pregnancy a figure of 8.5% is  
acceptable.45,66 
 For HbA1c % : normal value  less than 6.5,acceptable  level  6.5- 7.5%,high risk 
greater than 7.5%.24,45,48,66The A1C test has been shown to predict the risk for the 
development of many of the chronic complications in diabetes.24,49,101,104  
Expert opinion recommends HbA1C testing at least two times a year in patients 
who are meeting treatment goals (stable glycemic control) and more frequently 
(quarterly assessment) in patients whose therapy has changed or who are not 
meeting glycemic goals. 38, 24, 44,45,104 
3. Glycated serum protein (GSP) :  
Reflects average blood glucose control over preceding two weeks, albumin is the 
main component. Measurements of total GSP and glycated serum albumin (GSA) 
correlate well with one another and with measurements of glycated hemoglobin 
(A1C test).38,104 
GSP assay may be of value when A1C test cannot be measured or may not be 
useful i.e hemolytic anemias or with short-term changes (1–2 weeks) in glycemic 
status. Several methods have been described that quantify either total GSP or total 
GSA. Fructosamine assay is widely used.104,107 Values for GSP vary with changes 
in the synthesis or clearance of serum proteins. 104,107 Good control is stated to be < 
2.7mmol/L, Poor control > 3.5 mmol/L. These ranges are only correct when the 
albumin concentration is normal: 30-45 g/L.7,66 
3.Serum adenosine deaminase (AdA):  
AdA related to the proliferation and differentiation of lymphocytes is suggested 
to be an important modulating enzyme for the bioavailability of insulin. Mensah 
et al demonstrated a positive correlation between AdA and GHbA1 as a function 
of hyperglycemia. They suggested that under condition of uncomplicated 
diabetes ie. without any infections (which raises AdA), serum AdA activity may 
be used to monitor long term diabetic control. It is relatively cheaper and could  
 be of value in situation where GHbA1 couldn’t be utilized .110 
Comprehensive management of type 2 diabetes 
Holistic approach has been recommended by US National Institute of Health, 
Institute of continuous Improvement (ICI) and ADA goals for management to 
address dyslipidemia, hyperglycemia, high blood pressure, microalbuminuria, 
prothrombotic diabetic state, smoking cessation7,24,46,111: 
Dyslipidemia: Goals are total cholesterol (TCH) < 200mg/dl, TG < 150mg/dl, 
HDL >45mg/dl, LDL <100mg/dl.These could be achieved through diet, fibrates 
and statins for TG, HDL and statins for LDL. Statins reduced CVD events by 15-
20%.46,111 
High blood pressure 
Multiple studies showed greater absolute benefit from controlling blood pressure; 
HOT study targeted diastolic<=80mmHG demonstrated 50% reduction in CVD 
events.111Targeting systolic B.P <130 resulted in 50% further reduction in 
mortality .46,111 Patients with renal insufficiency or proteinuria >1-2gm/24hours 
B.P target <120/75.24,56 Preferred first line is ACE-I, ARB; usually combination of 
drugs required 46,48,112 Aspirin together with statin resulted in 15-20% reduction in 
CVD events. 46,111,113 
Steno-2 trial had made it clear that intensive multiple risk factors approach in 
patients with microaluminuria would result in 50% reduction in macrovascular and 
microvascular events as compared to conventionally managed group. Their targets 
were: HbA1c<6.5%, BP<13/80, fasting TCH<170, TG<150 mg/dl . 
All patients received aspirin. Curves representing time to first event for the two 
groups continued to diverge throughout follow up for 8 years.114HOPE study 
showed that ACE-I decreased CVD events by rate of 25% inpatients without 
microalbuminuria. 111 
 
 
 
Prevention   of   diabetes 
Diabetes is chronic, progressive and degenerative. Its onset can pre-date the 
diagnosis by up to 10 years Up to 20% of patients have detectable retinopathy at 
diagnosis.Tuomilehto et al (the Finish trial) have shown that effective life style 
changes (changing overweight, central obesity, physical inactivity, high fat and 
energy diets) can prevent diabetes and improve quality of life.115 After 4 years, the 
lifestyle intervention group had reduced the risk of developing type 2 diabetes by 
more than 50%, despite a modest average weight loss of 7lbs or less than 5% total 
body weight116.In US Diabetes Prevention Programme (DPP) subjects who 
changed their lifestyle had reduced their risk of developing  type 2 diabetes by 58 %   
The lifestyle intervention was effective for subjects of all ages and ethnic groups. 
Subjects with standard care (no lifestyle intervention) plus metformin reduced their 
risk of getting type 2 diabetes by 31 %.117How would this interesting intervention 
be applied in health delivery system remains to be designed to help reducing one 
major chronic disease of our century.  
OBJECTIVES OF THE STUDY 
-To explore the relations among blood glucose levels at different times related to 
breakfast; fasting (FBG), 2 hour (2HPBG), 3 hour (3HPBG) post breakfast. 
-To examine the relationship between HbA1c and Blood glucose levels at fasting, 
two hour and three hour post breakfast. 
-To evaluate the power of each blood glucose test in inferring glycemic control 
when correlated to HbA1c. 
-To study the relation between postprandial glycemia and occurrence of long term 
complications of diabetes. 
-To study the effect of oral antidiabetic on different blood glucose parameters 
 
 
 
 
 
 
 
 
 
 
 
 
 
Study Design and methods: 
  Our study is an outpatient based cross sectional; descriptive and comparative 
study. It was carried in the period September 2002-May 2003, at Gaber Abuelez 
diabetic center, situated in Khartoum 2 about two kilometers south to Khartoum 
teaching Hospital. Registered diabetics were 9224, with a daily flow of 40-50 
patients, around 10-15 were new cases.  From those attending the diabetic clinic 99 
Sudanese patients diagnosed with type 2 diabetes were selected by the study 
investigator .Sample size was calculated according to the formula: 
              N=z2   (PQ)/d2                , z: CI: 1.96=95% in the z table 
 P: prevalence =5% , the maximum for diabetes in northern Sudan. q: 1-p, d: 
design defect =0.0025 
The selected patients had satisfied the selection criteria of being on no- insulin 
treatment; no change in treatment or life style within the three months before the 
study; no concomitant chronic disease or recent acute illness; and willingness to 
return to the clinic three times in one day, three times in one month to measure 
blood glucose. Those with diabetes diagnosed within the previous 6 months & 
pregnant ladies were excluded. They had given their informed consent. 
Of the total 99 enrolled (45% men and   55%   women) 68 completed the study. 
The mean age was 55.66+/-9.86, duration of diabetes averaged 8.91+/-7.31years. 
Treatment consisted of diet only in18.2%% of patients, sulfonylurea in 58.6%, 
metformin in 4.1 %    and combination of both metformin and sulfonylurea in 
19.1%.      
  Methods: Patients taken randomly were interviewed using a pre-tested and pre-
coded questionnaire and check-list for physical examination. Each patient came to 
the diabetic clinic in the morning (8-8:30) after 10-to14 –hour overnight fast. At 
the time venous blood was withdrawn to measure blood glucose. The patient then 
returned to the clinic to measure blood glucose 2h after breakfast (10-10:30), then 
1 hour later (3h) (11:30-12:30) .The process was carried out three times (7-14 days 
apart) over one month period at the end of which venous sample withdrawn and 
HBA1c was measured according to specified protocol118.Serum cretinine, Hb,urine 
general,ECG were done.   
Patients were asked to follow their usual treatment and eat their usual diet during 
the study duration. Patients past glucose profiles were reviewed; however only few 
had done both FBG&2HPBG.  
Patients who failed to show up were phoned and asked to return. Those who didn't 
show up were substituted.  
Analytical determinations: 
Blood samples were centrifuged within 1hour after blood withdrawal for 
immediate assessment of blood glucose (using gluco-oxidase: GOD; Enzymetic 
colorimetric test, GOD-PAP method, CRESCENT DIGNOSTICS,KSA).Blood for 
HbA1C was kept in EDETA containing bottles at 8º C. HbA1c was measured 
within 3-7 days using HbA1C chromatographic-spectrophotmetric, Ion exchange-
Temperature independent, biosystems reagents & instruments, Germany. Spectra 
model 270, spectrophotometer Sherwood, Cambridge, England. was used to read 
the values of glucose, HBA1C, creatinine. 
Statistics: 
Standard procedures were used to calculate the means, SD, SEM and simple 
correlation coefficients. Analysis of variance, x2 tests, paired t test ,ANOVA, 
multivariate logistic analysis multiple linear regression analysis were used. In the 
latter, fasting glucose and all the postprandial glucose levels were included as 
explanatory variables for HbA1c. 
The cut off point for good glycemic control was 7% for HBA1c, 6.6mmol/l 
(120mg/dl) for fasting glucose, 160mg/dl (8.9mmol/l) for postprandial glucose. 
118,119 Accordingly an increase >2.2mmol/l(40mg) in  glucose levels 2h/3h after the 
meal was regarded as exaggerated118,119,120Correlation significance and 
independence among fasting, 2&3h glucose were evaluated. Soft ware SPSS 
programme was used in statistical analysis. 
RESULTS 
Demographic data: 
A sample of 99 diabetic patients was studied. 56% were females (Figure 1). The 
average age was 55.6 years+/-9.86.The most frequent age was 45. 76.9% were 
more than 45 years (Figure 2   ). 
 Figure 3 Shows the residence of patients .The majority were coming from 
Khartoum .Most of the patients were of low socioeconomic status. 
Figure 4 shows the tribal distribution of the patients. The  most common tribe is 
gaaleen which represented 26.2%, followed by danagla 12.6%, mahsi 11.6, the rest 
of Arab dominant tribes  constituted 32.4%, and the rest (<20%) were from the 
West and South.  
Figure 5 presents the education status of the patients .Less than 10% had high 
school education or above.  
Clinical Features: 
Figure 6 shows the distribution of patients according to their boy mass index. The 
average BMI was 27.4947+/-4.54 kg/m2 .65.5% of patients were overweight or 
obese. Obesity ( BMI > 30) occurred in 31.1%. 
Figure 7 presents  types of treatment used  by the studied group. Sulfonylurea was 
the first line of therapy; more than 50% of patients were using the drug. Only 4% 
was using metformin. 
Family history of diabetes was found in 68.7%. Distribution of paternal and 
maternal antecedence was 33.3% and 25.5% respectively, a quarter had at least one 
sibling with diabetes. 
 
Diabetic Complications: 
Hypertension was demonstrated in 42.2% but those with history and/or on 
treatment was 21.4% .History of DKA was reported in 7.1%. Hypoglycemic 
episodes occurred at higher rate 12.1%, nevertheless only one case necessitated 
hospitalization.  
Table 1 shows the prevalence of complications in the studied group: cataract was 
seen in 13.2% with a trend towards increasing with increase in the duration of 
diabetes. Retinopathy was found in 24% of patients, in 8.15% was proliferative. 
11.1% reported receiving photocoagulation. Poor correlation was seen between 
complications, presence of hypertension and  the magnitude of hyperglycemia 
 Neuropathic complaint was reported in 29.3% but abnormal sensation 
demonstrated in only 10.1%  .There was a trend of increasing prevalence with 
longer duration of diabetes. It doubled at every five years increase, albeit no 
significant difference was shown between 10-15 and more than 15 years 
(P=<0.05). 
Significant drop in blood pressure was shown in 16.2%. A similar percentage 
occurred for erectile dysfunction. Nearly 80% was known diabetic for more than 
10 years. No relation to high blood pressure was found. 
 Overt proteinuria wasn't shown in this sample nor was past history of 
nephropathy. All patients had normal creatinine values. However when Crocroff-
Gault formula was used to calculate creatinine clearance (CC), the average CC was 
96.95+/-28.323 ml/min. 10.8% showed value of less than 60 ml/min .24.3% had a 
value that fall in the range of renal insufficiency (60-85ml/min).  
Diabetic foot mainly septic (DSF) was reported in 10.1%. 
4% were being treated for CHD. Of the 24% who brought forth their ECG, positive 
findings shown in 5.7% mainly features of left ventricular hypertrophy (LVH)& 
premature ventricular ectopics (PVE). 
No evidence of peripheral, carotid disease or TIA/stroke was found in this group of 
patients. 
Behaviour of patients towards their disease  
16.4% admitted to smoke. 62.5% smoked more than 10 cigarettes a day.  75.8% 
claimed checking regularly their blood glucose. However,  one third did that on 
feeling bad and 8 % did it twice per month .Half of the patients (50.7%) measured 
their blood glucose. Blood glucose control was poor and a few managed to show 
persistence for more than a year.  
Only one third kept records of follow up (30.3 %); 91% of them measured fasting 
blood glucose and just 9 % had done 2 hours postprandial blood glucose. 
Satisfactory control was shown in 26.4% very much in agreement with the study 
measurement (73.7% had FBG values more than 140 mg/dl).14% from the studied 
group owned glucometers but a few used it for SMBG, among reasons forwarded 
were their doubts in its reliability and being advised by their  treating doctors 
against its goodness. A good number did not know how to use.  
From the 99 patients only 3 % had measured their HbA1c and that was for one 
time .The majority of the patients were not aware about it. Lipid profile hadn't a 
better stance as only 6.1% had measured their lipids.  
Adherence to therapy was generally good, being higher for medication (84.4%) 
and less so for diet (69.7%) 
Glucose profiles 
Blood glucose averaged 174.12+/-59.79mg/dl (9.67mmol/l) in the fasting state, 2h 
after breakfast was 247.1+/-72.072mg/dl (13.72mmol/l) and at 3h was 224.49+/-
76.84mg/dl. 
Blood glucose was significantly lower in the fasting than the fed state. 
Most patients 79.4 % had glucose level of >120mg/dl before breakfast (FBG), only 
20.9% (n=14) showed good control ( <120mg/dl ).Most patients had blood glucose 
level >160mg/dl post meal: 91.2 %%( 62) at 2 h after breakfast, only 8.8 %( 6) 
showed satisfactory postprandial control. 87.3% showed value >160mg/dl at 3h 
after breakfast in single determination, whereas in mean values (three readings 
over one month time) the percentage was 70.6%(48), 29.4% showed values 
<160mg/dl (20).When the cut off point for three hour post breakfast was reduced 
to 140mg/dl, 83.8%(57) of patients recorded blood glucose value more than 
140mg/dl, 16.2%(11) <140mg/dl. Among patients with FBG less than 120 mg/dl 
(20.6%), 82 % had levels more than 160 mg/dl after 2h, 29.4% had levels more 
than 160 mg/dl after 3h from breakfast, and the percentage went to 70% for 3h 
levels more than 140mg/dl. 
The average absolute increase in blood glucose 2h, 3h after breakfast (over the 
fasting blood glucose levels) was 73.0098+/-40.1855 mg/dl and 50.370 +/-41.846 
mg/dl respectively.  
The frequency of distribution showed that blood glucose excursion 2h after 
breakfast was >40 mg/dl in 79.4% of patients, whereas that of 3h post breakfast 
was in 55.4%. The difference in glucose values at 3h and 2h following breakfast 
averaged 22.6397+/-33.5477 mg/dl ; favoring the 2h which was higher than 3h 
glucose  in 80% of samples. 
  
 
HBA1c: 
HBA1c averaged 8.474%+/-1.9 7.We found that 25% of patients had values less 
than 7 % .Among them 47.05% had fasting glucose more than 120mg/dl, 82% 2h 
excursion more than 40mg/dl and 29.4%  excursion more than 40mg/dl at 3h 
postbreakfast. 
Correlations: 
Table 2, 3 reports  the simple correlations among blood glucose levels at different 
times related to breakfast.  That between FBG &2h was 0.830 for the average 
means ,when computed at single determination it was 0.82 (p<0.0000),between 
FBG &3h was 0.841, between 2 h & 3h approached one in single determination 
0.912 (p<0.0000)& 0.900 for the average means. All of the correlations were 
highly significant but that between 2h&3h and fasting wasn't particularly strong for 
average means. 
Table 4, 5 presents simple correlations between HBA1c and blood glucose at 
different times related to breakfast. The correlation coefficients were significant 
between fasting and 3 hour post breakfast and HbA1c at r= 0.601and 
0.547(p<0.000) respectively.  
The relationship between the fasting glucose levels and HbA1c was particularly 
strong. The correlation between HBA1c and changes of glucose at 2 hours after 
meal was weak but positive correlation was shown at single determination. 
Table 6 presents correlations among glucose excursions. It shows the significant 
increase of glucose from the fasting value at 2&3 h, and the changes at 3 h from 
the glucose levels at 2 h. The correlation between glucose excursion at 2h and 3h 
was strong r= 0.666(P=0.000).The excursion between 2h &3h has half the r value 
of 2h glucose excursion r=0.367(P=0.002).Negative correlation was found between 
glucose excursion at 3h post breakfast and the excursion between 2h &3h 
r=0.449(p=0.000).  Paired T test for glucose excursions at 2h and 3 h post 
breakfast is shown in (table 7). Paired T test of different blood glucose levels 
showed that the difference between FBG and 2h  post breakfast glucose when 
grouped and when paired is significant (t = 14.982,p= 0.000, CI: 95%).Also the 
differences between 3 h post breakfast glucose and FBG(9.926;p = 0.000).The 
difference in values of 2h&3h was significant but  t value  was remarkably low( t = 
5.565,p= 0.000).Although differences were significant, 2h increased by 22.64mg/dl 
more than 3 h glucose, the maximum difference never exceeded 30 mg/dl and the 
lower was 14.59 mg/dl; confidence interval was 95%.In less than 10 %  of patients 
3h glucose was more than 2 h glucose. The correlation between the two values was 
0.900. 
Table 8 shows the relationship among blood glucoses at different times related to 
breakfast .It presents their values in predicting glycemic control when the glycated 
haemoglobin was taken as  the standard; control was classified as good when  
the value of HbA1c is les than 7% and poor when it exceeds 8.5%. 
Table 9 summarizes the main clinical features of diabetes including different 
glucose parameters correlated to different types of treatment. The duration in males 
averaged 11.4 years, that in females was shorter with  a mean of 6.91 years 
Table 10 shows the correlation between long term diabetic complications and the 
different parameters of blood glucose control using ANOVA, no significant 
association had been demonstrated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Figure (1)
 Distirbution of sex patients
 In Non-Insulin-Treated Type Two Diabetes
In Khartoum State 2003
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Figure No. (2)
  Patients Age distribution
 In Non-Insulin-Treated Type Two Diabetes
In Khartoum State 2003
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Figure No.(3)
 Patients distribution according to residence
In Non-Insulin-Treated Type Two Diabetes
In Khartoum State 2003
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Figure (4)
 Patients Distribution According To Tribe
In Non-Insulin-Treated Type Two Diabetes
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Figure No. (5)
Patient Education 
In Non-Insulin-Treated Type Two Diabetes
In Khartoum State 2003
  
 
 
 
 
 
 
 
 
 
Figure No. (6) 
Prevalence of Obesity
In Non-Insulin-Treated Type Two Diabetes
In Khartoum State 2003
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Table (1) 
Figure (7)
 Treatment OF Type Two Diabetic Patients
Khartoum State 2003
18%
59%
4%
19%
Diet Sulphonylurea Metformin Sulphonylurea + Metformin
Prevalence of long term complications in non-insulin treated type 2 diabetic 
patients-Khartoum 2003 
Cataract retinopathy Neurop
athy 
CHD Diabetic foot Postural 
hypotension 
Erectile 
dysfunction
 
8.1% 24% 10.1% 5.7% 10.1% 16.1% 16.3% Exami
13.1% 11.1% 29.1% 4%    History
CHD: Coronary heart disease. ED: erectile dysfunction. Exam: Clinical 
examination 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table (2) 
Simple correlation of blood glucose levels at different times related to breakfast in 
non-insulin treated type 2 diabetes – (single determination)-Khartoum 2003 
Blood glucose 
N=97 
Correlation P value 
FBG vs.2hPBG 0.820♣♣ 0.000 
3hPBG vs.FBG 0.727♣♣ 0.000 
3hPBG vs.2hPBG 0.912♣♣ 0.000 
♣♣Correlation is significant at 0.01 level (2-tailed). FBG: Fasting blood glucose, 
2hPBG: Two hour post breakfast blood glucose.3hPBG:Three hour post breakfast 
blood glucose 
 
 
 
 
 
 
 
 
 
 
 
 
Table (3) 
Simple correlation of blood glucose levels at different times related to breakfast in 
non-insulin treated type 2 diabetes –Khartoum -2003 
Blood glucose 
N=68 
Correlation P value 
FBG vs.2hPBG 0.830♣♣ 0.000 
3hPBG vs.FBG 0.841♣♣ 0.000 
3hPBG vs.2hPBG 0.900♣♣ 0.000 
♣♣Correlation is significant at the 0.01 level (2-tailed): Means were used to  
determine the values. FBG: fasting blood glucose, 2hPBG: two hours post 
breakfast blood glucose.3hPBG: three hours post breakfast blood glucose 
 
 
 
 
 
 
 
 
 
 
 
 
Table (4) 
Simple correlation between HbA1c and blood glucose levels at different times related to 
breakfast in non-insulin treated type 2 diabetes (Single determination)–Khartoum -2003 
Blood glucose 
N=97 
Correlation P value 
HbA1c vs. FBG 0.584♣♣ 0.000 
HbA1c vs.3hPBG 0.649♣♣ 0.000 
HbA1c vs.2hPBG 0.669♣♣ 0.000 
Correlation is significant at 0.01 level (2-tailed).FBG: Fasting blood 
glucose.2hPBG: Two hour post breakfast blood glucose.3hPBG: Three hour 
post breakfast blood glucose 
 
 
Table (5) 
Simple correlation between HbA1c and blood glucose levels at different times 
related to breakfast in non-insulin treated type 2 diabetes –Khartoum -2003 
Blood glucose 
N=68 
correlation P value 
HbA1c vs.FBG 0.601♣♣ 0.000 
HbA1c vs.2hPBG 0.202 0.102 
HbA1c vs.3hPBG 0.547♣♣ 0.000 
            ♣♣Correlation is significant at 0.01 level (2-tailed) .Means were used  
    to determine the values. Correlation is significant at the 0.01 level (2-tailed): 
    FBG: Fasting blood glucose, 2hPBG: Two hour post breakfast blood glucose. 
   3hPBG: Three hour post breakfast blood glucose 
 
 
 
 
 
 
 
 
 
 
 
 
 Table (6) 
Glucose excursions in non – insulin treated type 2 diabetics Khartoum 2003 
Glucose excursions relations Correlations: P value 
At 2 hours (FBG –2hPBG) vs. 
3 hours (FBG- 3hPBG). 
2 hours vs. (3hPBG-2hPBG)  
3 hours  (3 hPBG- FBG)vs.  
(3h BG-2hPBG) 
 
0.666 
 
0.367 
 
-0.449 
0.000 
 
0.002 
 
0.000 
Correlation is significant at 0.01 level (2-tailed) .FBG: Fasting blood glucose, 
2hPBG:Two hour post breakfast blood glucose.3hPBG:Three hour post breakfast 
blood glucose 
 
Table (7) 
Paired T test for glucose excursions at different times related to meals 
  in non – insulin treated type 2 diabetics -Khartoum 2003 
 F B G vs. 2 h BG 
n=67 
2 hPBG vs. 3 hPBG 
n=67 
3 hPBG vs. FBG  
n=67 
Paired 
difference 
73.010+/–
0.185mg/dl 
S E M 4.873  
22.64+/–33.54 
mg/dl 
SEM 4.068 
50.370+/–41.846 
mg/dl 
SEM 5.075. 
C.I 95% 63 – 82.283 mg/dl 14.519–0.760mg/dl 40.241–60.455 mg/dl 
T test 14.982 5.565 9.926 
P value 0.000 0.000 0.000 
Correlation is significant at 0.01 level (2-tailed). CI: Confidence interval   SEM: 
Standard error of the mean. FBG: Fasting blood glucose. 2hPBG: Two hour post 
breakfast blood glucose.3hPBG: Three hour post breakfast blood glucose 
 
 
Table (8) 
The relationships among blood glucoses at different times related to 
 Breakfast in non – insulin treated type 2 diabetics – Khartoum 2003 
HbA1c 
N = 67  
Less than 
7% 
N=17 
7 – 8.5% 
n=20 
Mare than 
8.5%  
n = 30 
Tests P  
FBG<120mg/dl 
FBG> 120mg/dl 
9 (529%) 
 
8(47.88) 
3 (15%) 
 
17 (85%)
2 (6.66%) 
 
28 (93.3%) 
Pearson x2 
Likelihood ratio 
Linear/linear 
association 
 
0.00
0 
0.00
0 
0.00
0 
2 h excursion  
< 40 mg/dl 
 
>40 mg/dl 
  
 
3(17.64%) 
 
14(82.35%)
 
2 (10%) 
 
18(90%) 
 
1 (3.33%) 
 
25(96.66%) 
Pearson x2 
Likelihood ratio 
Linear/linear 
association 
 
0.25
1 
0.24
8 
 
0.59
9 
3h Excursion  
<40 
> 40 
 
12(70.58%)
5 (29.4%) 
 
6 (30%) 
14 (70%)
 
2 (6.66%) 
28 93.33%) 
Pearson x2 
Likelihood ratio 
Linear/linear 
association 
 
0.00
0 
0.00
0 
 
0.00
0 
 
Correlation is significant at 0.01 level (2-tailed). FBG: Fasting blood glucose, 
2hPBG: Two hour post breakfast blood glucose.3hPBG: Three hour post breakfast 
blood glucose.HbA1c: glycated hemoglobin 
 
Table (9) 
Main features and glucose parameters correlated to treatment in non-insulin treated 
type 2 diabetic patients -Khartoum 2003 
N=68 Diet  SU MET MET +SU P 
Sex male female male female male female male female  
AGE 
(Years) 
55.86 510 56.84 55.85 60 51 59 53.56 0.630
Duration 
of diabetes 
(Years) 
8.14 5.6 11.92 6.84 1.5 4 14.4 10.67 0.021
BMI 25.84
41 
29.6836 24.9482 28.014 25.6029 29.5129 27.92 30.3581 0.352
FBG 
mg/dl 
107.3
00 
144.556 173.850 173.850 158.25 295.33 197.417 198.2 0.021
2HBG 
mg/dl 
175.9
67 
202.83 246.158 252.758 262 390.000 260.28 261.983 0.035
3HBG 
mg/dl 
138.9
87 
183.722 223.67 23.4.652 241.083 293.333 234 250.685 0.049
Hb A1c % 5.760 8.233% 8.62 8.436 8.9 9.6 9.35 9.225 0.024
BMI: body mass index.   Average duration in females is 6.91 years. Average 
duration in males is 11.41 years. FBG: Fasting blood glucose. 2hPBG: Two hour 
post breakfast blood glucose.3hPBG: Three hour post breakfast blood 
glucose.HbA1c:glycated hemoglobin.SU: sulfonylurea. MET: Metformin. 
Correlation is significant at 0.01 level (2-tailed). 
 
Table (10) 
Correlation of Long term diabetic complications with different glucose parameters 
in non-insulin treated patients with type 2 diabetes- Khartoum 2003 
 
N=68 FBG 2hPBG 3hPBG HbA1c 
Diabetic retinopathy 0.762 0.127 0.236 0.181 
Somatic neuropathy 0.655 0.391 0.962 0.226 
Autonomic 
neuropathy 
0.593 0.218 0.433 0.933 
CHD 0.468 0.661 0.362 0.531 
Diabetic foot  0.793 0.673 0.617 0.749 
FBG: Fasting blood glucose. 2hPBG: Two hour post breakfast blood 
glucose.3hPBG: Three hour post breakfast blood glucose.HbA1c: glycated 
hemoglobin. CHD: coronary heart diseases 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
 
Demographic data: 
In studied group of 99 females represented 56% which agreed with literature. 
Elmahadi showed 65% predominance.44Age averaged 55.6 years+/-9.86,76.9% 
was more than 45 years. Majority of patients resided in Khartoum. Most patients 
were of low socioeconomic status, this may indicate that diabetes is becoming 
more popular among the poor in contrast to literature: diabetes is common in the 
poor sector of affluent countries but in the rich in underdeveloped8 or the fact that 
most of the rich go to private centres weaken this conclusion. The most common 
tribe is gaaleen at 26.2%, followed by danagla and mahas12.6%, 11.6, Bagir12 et al 
demonstrated danagla tribe to be most affected with diabetes (8%) than other 
northern tribes. western, southern tribes constituted less than 20% much in 
agreement with Bagir et al.5,13 Vast majority of patients had received not more than 
primary education which would have negative impact over the management of 
diabetes which became more complex in recent years. 
 Clinical Features: 
Most of the patients are overweight or obese with BMI mean of 27.4947 +/-4.54 kg 
per square metre, 65.5% of patients were overweight & 31.1% obese. Females are 
more inflicted by obesity; these approximated figures in literature.7,8,121 ElMahadi 
et al44 reported figure of 46.2%.  
Obesity is on increase in Sudan and could be responsible for the increasing 
prevalence of diabetes type 2, which has reached epidemic rates world wide as 
direct result of improvement in people income and westernization of life style.121 
 NICE guidelines recommend113 the use of orlistat (Xenical) when BMI exceeds 28 
and the patient manages to lose 2.5 kg on diet in order to improve control of 
diabetes. Most oral hypoglycemic drugs cause gain in weight, less so is metformin 
which was used alone in 4% of our patients and in 19% in combination with 
sulphonylureas .Sudanese diabetic with type 2 are increasingly obese/overweight 
metformin should be the first line treatment. Use of weight lowering interventions 
including orlistat should be strongly considered. 
Family history of diabetes was found in 68.7% near to 63% demonstrated by 
Elmahadi.44 Distribution of paternal and maternal antecedence was 33.3% and 
25.5% respectively, a quarter has at least one sibling with diabetes. This goes well 
with other studies and supports the heritable component of type 2 diabetes but 
leave the question open for a third of patients with no family history of diabetes. 
8,44 
Diabetic Complications: 
Hypertension was demonstrated in 42.2%,but only half of them were known to 
have  hypertension(previously diagnosed and on treatment) .This  is similar to that 
reported by Ahmed M el-B 44%121but less than that reported by Elmahadi 
(12.9%).17It comply well with that reported in UKPDS48 and other studies.49,50 
Hypertension affects at least half of patients with diabetes.49  
In UK prospective diabetes study tight blood pressure control (mean 144/82 mm 
Hg) achieved significant reductions in the risk of stroke (44%), heart failure (56%), 
and diabetes related deaths (32%), as well as reductions in microvascular 
complications (for example, 34% reduction in progression of retinopathy). One 
third of patients required three or more antihypertensive drugs to maintain a target 
blood pressure <150/85 mm Hg.45,48,49Ahmed121 failed to demonstrate significant 
correlation with age, duration of diabetes or nephropathy .Obesity could contribute 
to the high prevalence of hypertension in Sudanese diabetics. 
History of ketoacidosis (DKA) was reported in 7.1% which is less than that 
reported 51-52 but it reminds of the importance of type 2 in the events of DKA. 
Hypoglycemic episodes occurred at higher rate 12.1% but hospitalization was 
needed in one case. Cataract was seen in14.1% as compared to cataract (16%) 
reported by Elmahadi et al44 with a trend towards increasing incidence with 
increase in duration of diabetes (p=0.09).  
Microvascular complications: 
Retinopathy found in 24% of patients; higher than that reported by Elmahdi 
(17.4%) 44, proliferative type was seen in 8.15% despite 11.1% who reported 
receiving photocoagulation. This could point to the reduced sensitivity of direct 
ophthalmoscopy in the diagnosis of retinal changes in the diabetics. ICI, NICE and 
ADA recommend the use of both ophthalmoscopy and retinal photography on 
annual basis to detect retinal changes in diabetics; together they give sensitivity of 
a round 70%.7,8,16,24,45,49  
Poor correlation was shown with duration of diabetes, age of patients, fasting and 
2h glucose values but significantly correlated to presence of hypertension, HbA1c 
and 3h postbrekfast blood glucose(p<0.05). Neuropathic complaint is the 
commonest events being 29.3% however signs of peripheral neuropathy was 
demonstrated in only 10.1% in variance with Elmahdi 31.5%.44The discrepancy 
between symptoms and physical findings could be explained by the prevailing 
hyperglycemia which could account for neuropathic pains. 7,38  
Nerve conduction studies would have been more plausible in truly estimating the 
prevalence of peripheral neuropathy in type 2 diabetes. There was a trend towards 
increased prevalence with prolonged duration of diabetes, prevalence doubled with 
every five years increase, albeit no significant difference was shown between the 
group of 10-15 years  and more than 15 years (P=0.17). 
Overt proteinuria wasn't shown in this sample nor did patients give history of 
nephropathy. The study wasn't powered to estimate prevalence of incipient 
nephropathy. Elmahdi reported figure of 9.2%.44All patients had shown normal 
serum creatinine values. However when Crocroff-Gault formula was used to 
calculate creatinine clearance (CC) as an acceptable reflection of GFR 122 10.8% 
had value of less than 60ml/min, 24.3% had fallen in the range of renal 
insufficiency (60-85ml/min). This highlights the hazard of taking creatinine as 
screening test for renal dysfunction and that overt proeinuria doesn't on its own put 
subjects out of risk nephropathy. We recommend using this formula to estimate CC 
in the annual assessment for diabetics, it is simple &has high sensitivity. 122   
Autonomic neuropathy was common as evidenced by significant postural drop in 
blood pressure and erectile dysfunction (ED) in 16.2%.Nearly 80% was known 
diabetic for more than 10 years, significant correlation to duration of diabetes was 
found (p<0.05) but no significant association  to high blood pressure or degree of 
glycemic control. Awad &Ahmed123had reported higher prevalence of autonomic 
neuropathy 40%, peripheral neuropathy in 66%;  but their study included both 
types of diabetes and insulin treated type 2 with longer duration (mean = 16+/-7.3 
years) and perhaps severer disease.  
The prevalence of ED was probably higher due to under reporting. Erectile 
dysfunction is a common complication of diabetes, occurring in up to half of men 
aged over 50 years (compared with 15-20% in age matched non-diabetic men). It is 
of multifactorial aetiology non of the patients received any counseling or treatment 
despite the introduction of sildenafil in our market, which is reported to have a 50-
70% success rate in patients with diabetes.49  
Macrovascular complications 
Diabetic foot mainly septic (DSF) was reported in10.1%, however clinical 
evaluation revealed no evidence of carotid stenosis or TIA/stroke in this group of 
patients.  
Peripheral vascular disease and cerebrovascular disease were reported to be 3.4%, 
4.4% in Elmahdi &Mukhtar.44Elmahdi et al reported higher incidence of PVD of 
6.2% in another study but patients were insulin treated. 17 
Coronary heart disease(CHD) was shown by history in  4% compared  to 5.1% 
reported by Elamahdi.44 Of the 24% who brought forth their ECG's  positive 
findings were found in 5.7% mainly LVH,PVE and T wave inversions in 
anteriolateral leads . 
Macroangiopathic complications were significantly related to aging and 
hyperglycaemia. The absence of correlation between postmeal glycemia and 
cardiovascular complications in our study could be explained by the small number 
of patients who had CHD as the relation was well documented. 89-95 
 
Behaviour of patients towards their disease  
Smoking was common among the group (16.4%).62.5% smoked more than 10 
cigarettes a day. This adds much to the already heightened risk of vascular 
complications and should be targeted as cutting smoking resulted in 50% reduction 
of all cause mortality and morbidty24,49,113 . 
Monitoring of glycemic control in this group of patients was far from ideal  as one 
third checked their blood glucose  on feeling bad and only 8% did that twice per 
month .Half of patients (50.7%) did it monthly ,however  their glucose control was 
poor and few managed to show persistence for more than a year. Only one third 
had kept records for follow up (30.3%). 
The practice at the centre is to monitor fasting blood glucose or random glucose 
(91%) plus urine for sugar. 2hour post breakfast glucose was done scarcely (9%). 
More than two thirds of patients had poor glycemic control .Very much in 
agreement with glucose measurements of the study. 
14% from the studied group owned glucometers but few used it for SMBG, among 
reasons forwarded were their doubts in its reliability and being advised against it 
by the treating doctors. An appreciable number didn't know how to use it .This 
reflects poverty of knowledge among patients and doctors alike, more health 
education is needed to address these points. HbA1c was obviously wasn't 
acknowledged as method for glucose control; only 3% had ever measured HbA1c 
and for one time. Majority of patients were not aware about it .Its expense at 2500 
Sudanese Dinnars (9.5 $) further limits its utilization. Lipid profile wasn't better as 
only 6.1% had measurement, again translating major deviation from guidelines in 
Sudan specialized diabetic centre. 
 Adherence to therapy was generally good, being higher for medication (84.4%) 
but less for diet (69.7%). More than half of patients were using sulphonylureas, a 
round 20% on combined metformin and sulphonylureas and only 4% on metformin 
alone. Correlation between the type of treatment and BMI is poor. No patient is 
using any drug that targets postprandial glucose. 
 
 
 
 
 
 
 
 
Glucose profiles  
Most diabetic patients with apparently good control as inferred from HbA1c <7%, 
or by fasting <6.6% (120mg/dl) had indeed high glucose levels after meals and/or 
exaggerated glucose excursions following meals reaching unexpectedly high 
levels. In these patients one should consider using medications that are particularly 
effective in blunting postprandial glucose bursts.  
The study indicated that monitoring glycemic control and efficacy of treatment 
cannot be restricted to fasting glucose and HbA1c .Both of which are poor 
indicator of blood glucose levels at different times of the day especially 
postprandially 46,87-88  
3 h postbrekfast glucose which wasn’t assessed on its own in similar studies has 
proved a significant association with fasting, 2h post breakfast and HbA1c.Its 
relation to 2h was particularly strong at single determination, however less strong 
when the means of the two tests were computed(0.912,0.900 respectively). When 
means of values were computed the association was mildly stronger with the 
fasting values. Glucose excursion at 3 hours was significant and high with similar 
values and strength as that shown by Bonora et al120 at 3h post lunch and 3h post 
dinner. Its significance is comparable to that obtained at similar timing shown by 
Lerman (prelunch).88 3 h postbreakfast glucose could be an additive 
armamentarium in the array used in following glycemic control and could be used 
as an alternative to 2h and fasting, further studies are needed however. 
Avington87 and A French study had proved the strength of extended postprandial 
glucose (5hour post lunch) in predicting glycemic control and had shown it to be 
similar in power to 2 h post meal. Our study signaled out another option that is 
near in timing to the gold standard test preprandial (prelunch).1,88,119 Controlling 
fasting glucose alone ameliorates HbA1c only partially as in UKPDS48,whereas 
correcting glucose all throughout the day resulted in greater reduction of HbA1c as 
in DCCT84 and the Kumamoto study85.The differences between the two studied 
group was 1% in UKPDS and 2 % in DCCT & Kumamoto. 
These results pointed out that glucose levels in the post breakfast states are not 
merely a drift of fasting (prebreakfast) glucose but reflect the ability of the beta 
cells of the pancreas to mount an early phase (burst) of insulin secretion in 
response to food intake. Early insulin release is known to be impaired in the 
majority of diabetics and that bolus-basal (injection-basal) regimen is probably the 
best method to ensure optimal glycemic control.89-92 
We found HbA1c to be better correlated with fasting (r=0.601; P=0.000); similar to 
the result shown by Attbani (r =0.634; P less than 0.001).1243h postbreakfast 
glucose correlated well with HbA1c but less than that with the fasting 
glucose(r=0.547; p=0.000). Despite the strong correlation seen on single 
determination of blood glucose levels, HbA1c correlation to postprandial glucose 
mean levels is poor (r=0.202; p=0.102).This is hard to explain .It varies with 
results shown by Avington87 and Lerman88and others.118-119 However it is in 
agreement with Bonora.120 It is also consisted with the conclusion reached by panel 
of experts designed by ADA to review the available data on postprandial glucose 
101 and goes with Unger statement.45  
On multivariate regression analyses all glucose parameters were independent 
predictors of glycated haemoglobin. The most constant was 3 h postbreafast 
glucose which showed strong correlation when computed alone (P=0.00000), with 
fasting (P=0.000), with 2 hour (0.008) and when the three computed together only 
the 3h was significant (P=0.004).  
Individually both fasting and 2h postprandial glucose showed significant power in 
prediction of HbA1c; (p =0.00; 0.043 respectively).  
The correlation with 2 h postmeal was marginally significant. Possible explanation 
is that more hours are spent in the interprandial and nocturnal periods than in the 
postprandial phases; most Sudanese confine themselves to three meals. 
Consequently the average daily blood glucose, which is the main determinant of 
the extent of the glycation process, is a function more of interprandial and 
nocturnal glucose levels than of glucose spikes after meals.120 
Data from the National Health and Nutrition Examination Survey Studies 
(NHANES) and IOEZ  125-127 based on medications targeting postprandial glucose 
in patients who weren't given basal medications yielded a reduction in postprandial 
glucose but didn’t substantially change HbA1c. However when the two regimens 
were given they resulted in lower value of HbA1c. 102-103,125-127  
Thus assessment of HbA1c is poorly informative of the degree of postprandial 
glucose content. However postprandial glucose demonstrated well the degree of 
poor control. 
Recent studies have shown that postprandial glucose level might exert stronger 
deleterious effect on the cardiovascular system than does fasting glucose. 89-90 This 
has been further substantiated by the fact that when glucose control aimed at 
normalizing fasting glucose alone, as in UKPDS, the effect on macroangiopathy 
was minimal.48,128 
Our finding that HbA1c is essentially dependant on FBG might explain the 
minimal effect of controlling HbA1c on CVD as in UKPDS or Veteran 
Administration Cooperative Study. 99 Whereas targeting postprandial glucose, as in 
the Kumamoto or DIGAMI study129 had gained better cardiovascular outcome.  
Furthermore, numerous observational studies had documented the increased risk of 
CVD associated with postprandial and/or post challenge glucose.91-96 Several 
experimental trials had supported the injurious effect of postprandial glucose on 
arterial wall and its proatherogenic properties.89,93-94 
More studies are awaited to clarify the subject; whether HbA1c suffices or 
postprandial should take the lead as a goal of therapy, at least to prevent CVD. 
Comparing different glucose parameters& main clinical features with the type of 
treatment revealed that gender, duration of diabetes were major factors associated 
with the type of treatment but not the age or BMI, much in agreement with Bonora 
et al.120 Fasting blood glucose, HbA1c, 2 h post breakfast glucose, 3 h post 
breakfast glucose had shown significant correlations (P values, in order, were: 
0.021, 0.021, 0.024, 0.035, 0.049). 
The type of treatment showed marginal significance when correlated with 2& 3 h; 
the relation with fasting, HbA1c and duration of diabetes was strongly significant. 
The latter pointed to the progressive nature of type 2 diabetes and stressed the 
insignificance of anthropometric measures like BMI in the evaluation of glycemic 
control .BMI tends to increase due to gain in weight exerted by most of 
medications used in diabetes especially sulphonylureas. 
The fact that postprandial glucose levels were poorly correlated to the type of 
treatment given to the patient in contrast to fasting glucose and HbA1c (almost 
double P value) supports the innovation that the latter two are better correlated 
together and affect each other. 
It also elucidates that they were not strongly related to post meal glucose levels 
and/or glucose excursion. It further strengthens the accumulating evidence that if 
postmeal glucose is not targeted on its own, its control would be poor and that 
specified drugs are needed for optimal glycemic control. 
 The relation between 2 h & 3 h postprandial glucose is close. Diet like drugs 
poorly controlled postprandial glucose which further strengthens the conclusion 
above. 
Gender had a great impact on diabetes, female diabetics have poor 
prognosis7,8,18,24,45 .Females in all treatment groups were definitely overweight;  
with a mean BMI  of 28 kg/m2 .They had the worst glycemic control despite the 
shorter duration of diabetes with a mean of 6.91 years compared to 11.41 in the 
male group.  
The group using metformin and combined treatment had poorer glycemic control 
and more BMI values clearer in the male group; this could be explained by the late 
administration of these drugs in a group with prolonged duration of a progressive 
disease. 
The controversy in correlation between single day readings of 2 hour glucose and 
the means of 3 readings corresponds with the simple fact that blood glucose levels 
vary day by day. Good evidence exists to support that several glucose 
determinations over a period of several weeks are better correlated to HbA1c than 
a single or few determinations in one day.112 The positivity of correlation on single 
determination with 2 hour postprandial glucose and lack of correlation with the 
average values may be explained, at least in part by that patients during study 
period had complied better with treatment and adhered closer to diet. 
On average metabolic control was poor in most of  the patients, this consisted with 
data shown by ElMahadi and others.44,123 Considerable proportion of patients, 
many of whom showing satisfactory HbA1c level, indeed had poor glycemic 
control after meals.  
Because postprandial hyperglycemia is an independent risk factor for CVD in type 
2 diabetes specific periodic assessment of postprandial glucose seems to be 
warranted along with FBG. 
The significant position of 3hour post breakfast glucose signaled out in our study is 
an interesting finding .It could be extrapolated for 2 hours and/or fasting glucose in 
monitoring glycemic control. We suggested 140mg/dl as an upper limit. ADA 
recommended 140mg/dl level for the 2 hours postprandial.1  
Indeed diabetes type 2 is a progressive disease and glycemic control worsens over 
time. Nevertheless current guidelines and drugs used for treatment fail to achieve 
goals in most cases. Bolus-basal regimen is the best option available and should be 
adhered to. They mimic early and late rise of insulin. Oral bolus-basal regimen 
gives better control of both prandial and basal glucose. It delays the inevitable need 
for insulin.89-94When insulin is needed in the management; bolus injection of rapid 
acting insulin is wiser and gives better diabetes control.  
This modality of therapy neither restores the physiological functioning of B cells 
nor delivers insulin directly to the portal circulation where extensive hepatic 
clearance occurs then insulin is delivered into the peripheral circulation in a 
pulsatile fashion. The ideal drug which acts this way is still awaited.77-78 
 
 
 
 
 
Conclusion 
The main results of the present study are that: 
The majority of non-insulin treated type 2 diabetics in Sudan had higher than 
recommended blood glucose levels and exagerated glucose excursion after meals. 
High postprandial glucose was often found when long term control and fasting 
glucose were satisfactory. 
Three hour post breakfast glucose is strongly correlated to fasting, two hour and 
HbA1c. 
two hour post breakfast glucose demonstrated poor correlation with the level of 
HbA1c 
In prediction of glycemic control both fasting and 3h postbrekfast glucose had 
showed to be sensitive in reflecting both good and poor control. 
2hour postprandial glucose was found to be a poor predictor of good control but 
slightly more powerful than both fasting and three hour post breakfast in predicting 
poor glycemic control i.e HbA1c >8.5% . 
BMI was a poor indicator of glycemic control. Multiple regression analysis 
showed no significant association between diabetic complications and the different 
parameters used to monitor glycemic control in the study. 
Glucose monitoring in type 2 diabetes seems to be more complex than previously 
thought, because fasting blood glucose is a rather poor index of glucose levels 
throughout the day. 
 HbA1c seems to provide poor information on postprandial glucose levels and it 
provides no information on glucose excursion with meals in Sudanese patients. 
Remarkable proportion of patients with type 2 diabetes showed poor glucose 
control in the postprandial period, even when HbA1c was satisfactory. They might 
benefit from medications specifically suited for providing more physiological 
control after meal ie oral (injection)-basal therapy.  
Comprehensive management should entail monitoring not only FBG and/orHbA1c 
level but also glucose at other times especially in the postprandial period .2 hour 
postprandial glucose had been extensively studied, 3 hour postprandial glucose is 
an attractive option . 
Patients shouldn’t be denied the test for postprandial glucose if show later than the 
précised 2 hours. 2-3 hours is a more flexible goal. More studies are awaited. 
Home glucose monitoring will make adherence easy. 
In prevention of diabetic complications controlling postprandial hyperglycemia is 
at least as important as controlling fasting glycemia. Stricter control of 
postprandial glucose using specified drugs is likely to be useful in better control of 
glycemia and might result in better outcome in type 2diabetes.  
The management of diabetic patients in Sudan is poor; adherence to guidelines 
lacked and intensive health education is needed. 
 
 
 
 
Recommendations 
-Comprehensive management of type 2 diabetes should entails monitoring not only 
fasting glucose and/orHbA1c levels but also glucose at other times especially in 
postprandial period. 
-Patients shouldn’t be denied the test for post meal glucose if they show later than 
2hours. 2-3 hour postmeal glucose is a more flexible goal. 
-Home glucose monitoring (SBGM) will make it easier to follow up glycemic 
control and would involve the patient in participating actively in his/her 
management. 
-Intensive health education is direly needed in the field of diabetics care to address 
proper glycemic control, healthy life style and control of high blood pressure & 
dyslipidemia. 
-Training of medical personnel working in diabetic care centres and all health 
providing centres is needed for optimizing the management of diabetes; continuous 
medical education would be a necessity. 
- Methods to recruit interventions for primary prevention of diabetes should be 
developed and implemented in the health system. 
-The ideal treatment for patients with diabetes type 2 should include a combination 
of agents that lower basal plasma glucose and agents that control meal-related 
glucose excursions. 
-More studies are awaited to further elucidate the value of two and three hour 
postprandial glucose in monitoring glycemia and the impact of postprandial 
glycemic control on morbidity & mortality in type 2 diabetes in Sudanese patients. 
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